A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Caffeine (Primary) ; Capmatinib (Primary) ; Midazolam (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 24 Aug 2017 Planned End Date changed from 5 Jul 2017 to 12 Sep 2017.
- 21 Dec 2016 Status changed from recruiting to active, no longer recruiting.